Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Lancet Diabetes Endocrinol. 2021 Jun 29;9(8):502–514. doi: 10.1016/S2213-8587(21)00139-X

Figure 2:

Figure 2:

2-hr C-peptide AUC mean levels and 90% CI obtained from 4-hr MMTTs performed over the 24 month study in imatinib-treated versus placebo groups. The significance level at 12 months is p = 0·048 (one-sided); all other comparisons are not significant. In all figures, the imatinib-treated group is shown in blue, and the placebo-treated group in red.